| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Retension Pharmaceuticals, Inc.
13G
RTSN · 76135H100
|
7.4% |
10/15/2026
Event 10/13/2026
|
|||
|
Birchtech Corp.
13G
BCHT · 59833H200
|
5.2% |
10/5/2026
Event 9/29/2026
|
|||
|
Health In Tech, Inc.
13G
HIT · 42217D102
|
6.2% |
9/29/2026
Event 3/27/2026
|
|||
|
Rank One Computing Corp
13G
ROC · 753040104
|
5.1% |
8/20/2026
Event 8/14/2026
|
|||
|
MDxHealth SA
13G/A
Amendment 4
MDXH · B5950S113
|
19.5% |
8/17/2026
Event 8/13/2026
|
|||
| Laurence W. Lytton | 19.5% | ||||
| Lytton-Kambara Foundation | 12.1% | ||||
|
Aytu BioPharma, Inc.
13G/A
Amendment 3
AYTU · 054754858
|
4.99% |
8/14/2026
Event 6/30/2026
|
|||
| Lytton Laurence W | 4.99% | ||||
| Lytton-Kambara Foundation | 4.99% | ||||
|
LiqTech International, Inc.
13G/A
Amendment 6
LIQT · 53632A300
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 7.3% | ||||
|
Aprea Therapeutics, Inc.
13G/A
Amendment 1
APRE · 03836J201
|
3.2% |
8/13/2026
Event 6/30/2026
|
|||
|
IN8BIO, Inc.
13G/A
Amendment 1
INAB · 45674E208
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Capstone Energy Plus, Inc.
13G/A
Amendment 1
CEPL · 14067D607
|
5.4% |
8/13/2026
Event 6/30/2026
|
|||
| Lytton Laurence W | 5.4% | ||||
| Lytton-Kambara Foundation | 4.5% | ||||
|
DNA X, Inc.
13G/A
Amendment 8
SONM · 83548F309
|
6.8% |
8/13/2026
Event 6/30/2026
|
|||
|
Codexis, Inc.
13G/A
Amendment 1
CDXS · 192005106
|
5.2% |
8/13/2026
Event 6/30/2026
|
|||
|
Scientific Industries Inc
13G/A
Amendment 5
SCND · 808757108
|
9.9% |
8/13/2026
Event 6/30/2026
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 9.9% | ||||
|
MDxHealth SA
13G/A
Amendment 3
MDXH · B5950S113
|
9.6% |
8/13/2026
Event 6/30/2026
|
|||
|
Ideal Power Inc.
13G/A
Amendment 1
IPWR · 451622203
|
7.5% |
8/13/2026
Event 6/30/2026
|
|||
|
Rein Therapeutics, Inc.
13G/A
Amendment 1
RNTX · 00887A204
|
4.9% |
8/13/2026
Event 6/30/2026
|
|||
|
Guerrilla RF, Inc.
13G/A
Amendment 1
GUER · 40162G203
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
|
Data I/O Corp
13G
DAIO · 237690102
|
9.9% |
6/23/2026
Event 6/17/2026
|
|||
| Lytton Laurence W | 9.9% | ||||
| Lytton-Kambara Foundation | 5.8% | ||||
| AWL Family LLC | 2.9% | ||||
|
Sintx Technologies, Inc.
13G
SINT · 829392703
|
10.0% |
6/9/2026
Event 6/3/2026
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Talphera, Inc.
13G/A
Amendment 2
TLPH · 00444T209
|
2.5% |
5/15/2026
Event 3/31/2026
|
|||
| Lytton Laurence W | 2.5% | ||||
| Lytton-Kambara Foundation | 2.5% | ||||
|
TELA Bio, Inc.
13G/A
Amendment 4
TELA · 872381108
|
5.5% |
5/15/2026
Event 3/31/2026
|
|||
|
DNA X, Inc.
13G/A
Amendment 7
SONM · 83548F309
|
8.1% |
5/15/2026
Event 3/31/2026
|
|||
|
Creative Realities, Inc.
13G/A
Amendment 1
CREX · 22530J309
|
8.7% |
5/15/2026
Event 3/31/2026
|
|||
|
Rein Therapeutics, Inc.
13G
RNTX · 00887A204
|
5.8% |
5/6/2026
Event 5/1/2026
|
|||
|
Liberty Defense Holdings, Ltd.
13G
DETX · 53044R867
|
9.9% |
4/27/2026
Event 4/22/2026
|
|||
|
Codexis, Inc.
13G
CDXS · 192005106
|
5.0% |
3/11/2026
Event 3/6/2026
|
|||
|
IN8BIO, Inc.
13G
INAB · 45674E208
|
10.0% |
3/2/2026
Event 12/22/2025
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Ideal Power Inc.
13G
IPWR · 451622203
|
9.9% |
3/2/2026
Event 2/24/2026
|
|||
|
Aytu BioPharma, Inc.
13G/A
Amendment 2
AYTU · 054754858
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 8.8% | ||||
|
Stryve Foods, Inc.
13G/A
Amendment 3
SNAX · 863685202
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Talphera, Inc.
13G/A
Amendment 1
TLPH · 00444T209
|
5.9% |
2/17/2026
Event 12/31/2025
|
|||
| Lytton Laurence W | 5.9% | ||||
| Lytton-Kambara Foundation | 5.9% | ||||
|
DNA X, Inc.
13G/A
Amendment 6
SONM · 83548F309
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
|
Xtant Medical Holdings, Inc.
13G/A
Amendment 1
XTNT · 98420P308
|
5.5% |
2/17/2026
Event 12/31/2025
|
|||
| Lytton Laurence W | 5.5% | ||||
| Lytton-Kambara Foundation | 5.0% | ||||
|
Capstone Green Energy Holdings, Inc.
13G
CEPL · 14067D607
|
7.7% |
1/27/2026
Event 11/25/2025
|
|||
| Lytton Laurence W | 7.7% | ||||
| Lytton-Kambara Foundation | 7.7% | ||||
|
Elauwit Connection, Inc.
13G
ELWT · 28417M109
|
5.9% |
12/22/2025
Event 12/15/2025
|
|||
|
Aprea Therapeutics, Inc.
13G
APRE · 03836J201
|
9.9% |
11/17/2025
Event 11/13/2025
|
|||
|
TELA Bio, Inc.
13G/A
Amendment 3
TELA · 872381108
|
7.2% |
11/14/2025
Event 9/30/2025
|
|||
|
Sonim Technologies Inc
13G/A
Amendment 5
SONM · 83548F309
|
7.8% |
11/14/2025
Event 9/30/2025
|
|||
|
scPharmaceuticals Inc.
13G/A
Amendment 2
SCPH · 810648105
|
0% |
11/14/2025
Event 9/30/2025
|
|||
|
MDxHealth SA
13G/A
Amendment 2
MDXH · B5950S113
|
6.4% |
11/14/2025
Event 9/30/2025
|
|||
|
LiqTech International, Inc.
13G/A
Amendment 5
LIQT · 53632A300
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Aytu BioPharma, Inc.
13G/A
Amendment 1
AYTU · 054754858
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Lytton Laurence W | 10.0% | ||||
| Lytton-Kambara Foundation | 10.0% | ||||
|
Creative Realities, Inc.
13G
CREX · 22530J309
|
5.1% |
10/30/2025
Event 10/28/2025
|
|||
|
Talphera, Inc.
13G
TLPH · 00444T209
|
8.0% |
9/16/2025
Event 9/10/2025
|
|||
| Lytton Laurence W | 8.0% | ||||
| Lytton-Kambara Foundation | 8.0% | ||||
|
Guerrilla RF, Inc.
13G
GUER · 40162G203
|
10.0% |
8/25/2025
Event 3/28/2024
|
|||
|
Cellectar Biosciences, Inc.
13G/A
Amendment 4
CLRB · 15117F880
|
1.6% |
8/14/2025
Event 6/30/2025
|
|||
|
TELA Bio, Inc.
13G/A
Amendment 2
TELA · 872381108
|
8.5% |
8/14/2025
Event 6/30/2025
|
|||
|
Creative Realities, Inc.
13G/A
Amendment 6
CREX · 22530J309
|
4.2% |
8/14/2025
Event 6/30/2025
|
|||
|
Electrovaya Inc.
13G/A
Amendment 1
ELVA · 28617B606
|
4.7% |
8/14/2025
Event 6/30/2025
|
|||
|
Exagen Inc.
13G/A
Amendment 3
XGN · 30068X103
|
1.0% |
8/14/2025
Event 6/30/2025
|
|||
|
Sonim Technologies Inc
13G/A
Amendment 4
SONM · 83548F309
|
5.6% |
7/9/2025
Event 7/7/2025
|
|||
| Lytton Laurence W | 5.6% | ||||
| Lytton-Kambara Foundation | 4.5% | ||||
|
Sonim Technologies Inc
13G/A
Amendment 3
SONM · 83548F309
|
11.2% |
7/2/2025
Event 6/30/2025
|
|||
|
Aytu BioPharma, Inc.
13G
AYTU · 054754858
|
5.6% |
6/13/2025
Event 6/9/2025
|
|||
|
Sonim Technologies Inc
13G/A
Amendment 2
SONM · 83548F309
|
19.3% |
5/16/2025
Event 5/12/2025
|
|||
| Lytton Laurence W | 19.3% | ||||
| Lytton-Kambara Foundation | 11.2% | ||||
|
Evoke Pharma Inc
13G/A
Amendment 2
EVOK · 30049G302
|
3.9% |
5/15/2025
Event 3/31/2025
|
|||
|
SmartKem, Inc.
13G/A
Amendment 1
SMTK · 83193D203
|
4.9% |
5/15/2025
Event 3/31/2025
|
|||
|
NEUROONE MEDICAL TECHNOLOGIES Corp
13G/A
Amendment 2
NMTC · 64130M209
|
2.6% |
5/15/2025
Event 3/31/2025
|
|||
|
Creative Realities, Inc.
13G/A
Amendment 5
CREX · 22530J309
|
5.0% |
5/15/2025
Event 3/31/2025
|
|||
|
Biofrontera Inc.
13G/A
Amendment 2
BFRI · 09077D209
|
3.5% |
5/15/2025
Event 3/31/2025
|
|||
|
Xtant Medical Holdings, Inc.
13G
XTNT · 98420P308
|
6.8% |
4/16/2025
Event 4/15/2025
|
|||
|
Sonim Technologies Inc
13G/A
Amendment 1
SONM · 83548F309
|
17.8% |
2/24/2025
Event 2/20/2025
|
|||
|
Creative Realities, Inc.
13G/A
Amendment 4
CREX · 22530J309
|
6.3% |
2/13/2025
Event 12/31/2024
|
|||
|
Cellectar Biosciences, Inc.
13G/A
Amendment 3
CLRB · 15117F807
|
8.8%
Checked 5% or less
|
2/13/2025
Event 12/31/2024
|
|||
|
Duos Technologies Group, Inc.
13G/A
Amendment 6
DUOT · 266042407
|
4.99% |
2/13/2025
Event 1/31/2024
|
|||
|
MDxHealth SA
13G/A
Amendment 1
MDXH · B5950S113
|
8.4% |
2/13/2025
Event 12/31/2024
|
|||
|
Emcore Corp
13G/A
Amendment 4
EMKR · 290846401
|
1.4% |
2/13/2025
Event 12/31/2024
|
|||
|
Sonim Technologies Inc
13G
SONM · 83548F309
|
9.6% |
2/5/2025
Event 1/30/2025
|
|||
|
SmartKem, Inc.
13G
SMTK · 83193D203
|
9.4% |
12/23/2024
Event 12/20/2024
|
|||
|
Electrovaya Inc.
13G
ELVA · 28617B606
|
6.2% |
12/23/2024
Event 12/17/2024
|
|||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.